Sign up to save your podcasts
Or
Share Eli Lilly’s Stellar Financial Performance: Surpassing Expectations with Zepbound and Mounjaro
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Eli Lilly’s Stellar Financial Performance: Surpassing Expectations with Zepbound and Mounjaro
Eli Lilly’s fourth-quarter earnings surpassed market forecasts, buoyed by robust sales of Zepbound and Mounjaro, leading to $9.35 billion in revenue. However, the company’s stock experienced a slight downturn following the earnings announcement. Eli Lilly remains optimistic for 2024, expecting continued growth in sales and revenue. Find out more on FinanceVoyager
View all episodes
By Nathan DavisEli Lilly’s fourth-quarter earnings surpassed market forecasts, buoyed by robust sales of Zepbound and Mounjaro, leading to $9.35 billion in revenue. However, the company’s stock experienced a slight downturn following the earnings announcement. Eli Lilly remains optimistic for 2024, expecting continued growth in sales and revenue. Find out more on FinanceVoyager